Leadership & Pay ·
Promotes Andrew J. Silver as CFO; Raju Prasad steps down to pursue external opportunities
CRSPCRISPR Therapeutics AG
CRISPR Therapeutics AG promoted Andrew J. Silver from Senior Vice President of Finance to Chief Financial Officer, effective October 19, 2026. Mr. Silver will also serve as principal financial and accounting officer under a new employment agreement featuring a $515,000 annual base salary, a target bonus of 45 percent, and a one-time grant of 25,000 restricted stock units vesting in two years. Concurrently, outgoing CFO Raju Prasad resigned to pursue external opportunities but will remain employed through November 30, 2026. The company develops gene-editing therapies for serious diseases.